Codeine, an opioid analgesic and prodrug, poses significant risks in patients with severe liver disease due to impaired hepatic metabolism, leading to potential toxicity and reduced efficacy.
Contraindicated in severe hepatic impairment per guidelines; risk of fatal respiratory depression is heightened.
Monitor liver function and opioid effects frequently; avoid in decompensated cirrhosis.
Codeine may provide less pain relief due to poor activation to morphine.
Consider naloxone availability for reversal of overdose.
Codeine is primarily metabolized in the liver via CYP2D6 and CYP3A4 enzymes to its active metabolite morphine. Severe liver disease impairs these metabolic pathways, resulting in reduced conversion to morphine (decreased analgesia) and accumulation of codeine and its metabolites, prolonging exposure and enhancing opioid effects through altered pharmacokinetics.
Increased risk of respiratory depression, sedation, coma, and overdose; exacerbation of hepatic encephalopathy; prolonged half-life may lead to excessive CNS depression and hypotension; potential for worsened liver function due to stress on impaired organ.
Avoid codeine in severe liver disease if possible; if unavoidable, initiate at lowest dose with significant reduction (e.g., 50% or more), monitor closely for respiratory depression and sedation, and consider alternative non-opioid analgesics; consult hepatology and use short-acting agents sparingly.
Was this helpful?
The content on SafeTo is for informational purposes only and does not constitute medical, veterinary, or professional advice. Always consult with a qualified professional for specific concerns.
